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Abstract
Background: Information about health care use and costs of cutaneous T-cell lymphoma (CTCL) patients is limited,
particularly in a European setting.
Methods: In this population-wide study we set out to investigate prevalence, and trends in health care use in two
CTCL subtypes, mycosis fungoides (MF) and Sézary syndrome (SS) over a time period of 19 years in 1998–2016 by
using a nation-wide patient register containing data on all diagnosed MF and SS cases in Finland.
Results: The prevalence of diagnosed MF and SS rose from 2.04 to 5.38/100000, and from 0.16 to 0.36/100000 for
MF and SS respectively during 1998–2016. We found a substantial decrease in inpatient treatment of MF/SS in the
past two decades with a mean of 2 inpatient days/patient/year due to MF/SS in 2016, while the mean numbers of
MF/SS related outpatient visits remained stable at 8 visits/year/patient. Most MF/SS-related outpatient visits
occurred in the medical specialty of dermatology. In a ten-year follow-up after MF/SS diagnosis, the main causes for
outpatient visits and inpatient stays were MF/SS itself, other cancers, and other skin conditions. Also cardiovascular
disease and infections contributed to the number of inpatient days. Mean total hospital costs decreased from 11,
600 eur/patient/year to 3600 eur/patient/year by year 4 of the follow-up, and remained at that level for the
remainder of the 10-year follow-up. MF/SS accounted for approximately half of the hospital costs of these patients
throughout the follow-up.
Conclusions: The nearly 3-fold increase in prevalence of diagnosed MF/SS during 1998–2016 puts pressure on the
health care system, as this is a high-cost patient group with a heavy burden of comorbidities. The challenge can be
in part answered by shifting the treatment of MF/SS to a more outpatient-based practice, and by adapting new
pharmacotherapy, as has been done in Finland.
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Background
Cutaneous T cell lymphomas (CTCL) are a
heterogenous group of non-Hodgkin lymphomas charac-
terized by skin homing T cells. The most common type
of CTCL is mycosis fungoides (MF) accounting for
around 60% of new cases [1]. Sézary syndrome (SS) ac-
counts for 5% of CTCL cases. These two CTCL types
have often been grouped together in literature [1, 2].
MF/SS has an annual incidence of 5.6 per 100,000
person-years and the disease more commonly affects
males [3]. The evolution and prognosis of the disease is
dependent on the stage of the disease. The five-year
over-all survival rate of CTCL patients is over 80% in
the least advanced disease stages 1A and 1B, but
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worsens with tumour progression, and nodal and blood
involvement, declining to 18% for the most severe clin-
ical stages IVA2 and IVB [2].
There are many therapeutic options available for the
treatment of CTCL, with which long-term remissions
can be achieved [1]. The less advanced stages of MF are
usually treated with skin directed therapies, e.g. topical
corticosteroids and UV therapy to relieve symptom bur-
den. These treatment modalities require frequent out-
patient visits in hospitals. The advanced stages of MF
are treated with systemic therapies alone or in combin-
ation with skin directed therapy, or radiotherapy. Sys-
temic therapies for MF include chemotherapy,
monoclonal antibodies, extra-corporeal photoimmu-
notherapy, or biological response modifiers such as
interferon, retinoids, rexinoids and denileukin diftitox
[1]. Many forms of systemic therapy require hospitalisa-
tion of the patient, followed by frequent outpatient
visits.
CTCL patients have many comorbidities, both physical
and psychiatric. CTCL patients are in increased risk of
developing diabetes mellitus type 2, cardiovascular dis-
ease, a secondary cancer, or depression [4, 5]. There is
limited information about the role of these comorbidities
in the total health care use of CTCL patients [6, 7]. Fur-
thermore, the health care costs of CTCL and its comor-
bidities have not been reported for nationwide samples
using standard health economic evaluation methods in a
European setting.
As treatment options for MF/SS is an active field of
study, information on the total health care use and its
costs in this patient group may offer some beneficial
context. The purpose of this study was to examine
health care use among MF and SS patients in Finland:
patterns in inpatient stays and outpatient visits, as well
as the medical specialty in which MF/SS has been
treated. In order to capture also the role of comorbidi-
ties in the total health care use of MF/SS patients, we
formed a cohort of incident MF/SS patients and
inspected their total health care use during 10 years fol-
lowing diagnosis.
Methods
This study is a retrospective, population-wide non-
intervention study on mycosis fungoides and Sézary syn-
drome (ICD-10: C84.0 and C84.1) in Finland. The data
were collected from the national discharge register held
by the National Institute for Health and Welfare. The
discharge register covers all outpatient and inpatient sec-
ondary health care utilisation for the entire population
of Finland (~ 5.6 million) and includes unique personal
identification numbers for individuals which can be used
to calculate the exact number of individual patients. The
discharge register is regularly audited for completeness
and accuracy [8]. The stage of MF/SS cannot be identi-
fied from the national discharge register.
The methods used in the present study include i) cal-
culating the annual cross-sectional prevalence of diag-
nosed MF and SS in 1998–2016, and the respective use
of health care services to treat MF/SS (outpatient visits,
hospital admissions, bed-days), and ii) incident pooled
cohorts in 2000–2005 and the use and corresponding
costs of health care services for any cause in a follow-up
period of 10 years.
Prevalence was calculated as point prevalence for each
calendar year separately, using the size of the Finnish
population on Dec 31st of each year as the denominator.
Population size was acquired from the population regis-
ter maintained by Statistics Finland. Deaths of MF/SS
patients during the calendar year were not captured. Di-
agnosed prevalence was defined as the number of unique
patients who, during the calendar year, had outpatient
or inpatient health care contacts where the primary diag-
nosis or secondary diagnoses included one of the follow-
ing ICD-10 codes:
C84.0 (mycosis fungoides), or
C84.1 (Sézary syndrome).
In order for the patient to be classified as incident,
they could not have previous C84.0 or C84.1 related
health care use in 5 years prior to their index date. Index
date was defined as the first date when the patient had
an outpatient or inpatient health care contact where
C84.0 or 84.1 was the primary or secondary diagnosis.
However, the incident patients were allowed to have
prior health care contacts for other subtypes of C84.
This rule permits the inclusion of patients who pro-
gressed for instance from mycosis fungoides to Sézary
syndrome. MF and SS were grouped together due to the
low number of patients with SS, as has been done also
in previous CTCL literature [1, 2].
Using register linkage, all health care use for the
prevalent and incident patient cohorts were col-
lected. The health care services included outpatient
and inpatient care in hospitals and inpatient commu-
nity (primary) care. In our analyses, we grouped all
health care utilisation and costs into several separate
categories in the 10-year follow-up: 1) the total
health care utilisation and costs, 2) MF/SS related
health care utilisation and costs 3) total health care
utilisation and costs according to comorbidity such
as other cancer (C*), pneumonia and other infections
(J18* and A*), Disease of the skin and subcutaneous
tissue (L00*-L99*), Arthrosis (M15*-M19*), Cardio-
vascular disease (I2*-I6*), Depression (F32*-F33*),
and other diagnoses. In addition, all health care use
and costs were grouped according to medical spe-
cialty: oncology, dermatology, internal medicine,
other specialty.
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The costs for hospitalisations and hospital out-
patient visits due to any cause were based on the
NordDRG patient grouping definitions which use
the International Classification of Diseases 10th re-
vision (ICD-10) codes and the Finnish version of
the Nordic Classification of Surgical Procedures
(NCSP) codes for diagnostic and treatment proce-
dures [9, 10]. The DRG cost weights for hospitalisa-
tions and outpatient visits were based on
individual-level cost accounting data from several
hospitals, of which a national average was calcu-
lated and used in this study. The unit cost esti-
mates for community care bed-days were derived
from the national price list for unit costs of health
care services in Finland [11]. The cost of medica-
tion administered in the hospital is included in the
in the unit costs. For all cost analyses, we used the
2014 national average price level and the 2014 na-
tional standard price list, which was the latest ver-
sion available.
Results
Between 1998 and 2016, the prevalence of diagnosed
mycosis fungoides rose from 2.04/100000 to 5.38/
100000, and the prevalence of diagnosed Sézary syn-
drome rose from 0.16/100000 to 0.36/100000 (Table S1,
Additional file 1). Age distribution among MF/SS pa-
tients in 1998–2016 is presented in Fig. 1. Prevalence es-
timations for MF by sex and more detailed age group
can be found in Table S2, Additional file 1.
Hospital treatment of mycosis fungoides and Sézary
syndrome
Inpatient treatment of MF/SS has decreased in the past
two decades (Fig. 2). A notable decrease in inpatient
days per patient can be observed between the year 2007
and 2009, when the inpatient days drop by two thirds
from 6.7 to 2.1. Meanwhile, the mean number of hos-
pital outpatient visits for MF/SS per patient has
remained constant - MF/SS patients have, on average, 8
annual hospital visits related to their disease.
MF/SS related health care use by specialty in which
the patient was treated are presented in Fig. 3. Most
MF/SS-related hospital visits occurred in dermatology,
where their number grew notably during the 18-year in-
spection period (Fig. 3a). Most MF/SS-related inpatient
days took place either in dermatology or in “other” spe-
cialty (Fig. 3b). Some 57% of inpatient days in the
“other” specialty group occurred in a hospital, the rest in
a primary care inpatient ward.
Total health care use in a 10-year follow-up after MF/SS
diagnosis
A cohort was formed of all patients diagnosed with MF/
SS in 2000–2005 (n = 247). Ten years after diagnosis,
101 (41%) of these patients were still using hospital ser-
vices for any reason.
During the 10-year follow-up, the average number of
annual hospital outpatient visits per patient decreased by
50% from 18 to 9 (Fig. 4a). MF/SS was the cause for 40%
of all visits in the inspected cohort during year zero, i.e.
Fig. 1 Age distribution among all diagnosed Finnish MF/SS patients in 1998–2016
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year of MF/SS diagnosis. The proportion remained rela-
tively similar throughout the follow-up period. Besides
MF/SS, other common reasons for hospital visits were
other cancer and disease of the skin and subcutaneous
tissue.
The average number of annual inpatient days per pa-
tient decreased from 24 to 8 during the 10-year follow-
up (Fig. 4b). MF/SS was the main cause for inpatient
days during the first 4 years of the follow-up period,
after which MF/SS related inpatient days decreased dras-
tically in both absolute and relative terms. Other com-
mon reasons for hospitalisations were disease of the skin
and subcutaneous tissue, other cancer, cardiovascular
disease, and pneumonia and other infections.
Fig. 2 Hospital treatment of mycosis fungoides and Sézary syndrome patients. The blue bars represent the mean number of hospital outpatient
visits due to MF/SS per annum per patient, and the orange line represents the mean number of inpatient days due to MF/SS per annum
per patient
Fig. 3 MF/SS treatment by medical specialty. Hospital visits where the primary diagnosis was MF/SS are presented in figure a), inpatient days in
figure b)
Keto et al. BMC Health Services Research          (2021) 21:166 Page 4 of 8
Health care costs of MF/SS patients in a 10-year follow-up
The health care costs (hospital outpatient visits and
inpatient days) of MF/SS patients are presented as
mean costs in euros (€) per patient per year in
Table 1. The total costs were highest at the year of
MF/SS diagnosis, after which they declined until
reaching a steady state at year four. Costs for MF/
SS related health care use represented about half of
the total health care use of these patients through-
out follow-up.
Discussion
This nation-wide study describes trends in health care
utilisation among MF/SS patients during a 20-year
period in Finland. We are not aware of previous studies
with similar coverage, both population- and time-wise.
We report a nearly three-fold rise in prevalence of MF/
SS in 1998–2016, which could be due to the same rea-
sons as the increasing incidence trends in cutaneous T-
cell lymphoma observed in Norway, and possibly in the
United States of America as well, although the U.S.
Fig. 4 Total secondary health care use by cause among MF/SS patients in a 10-year follow-up after MF/SS diagnosis. Mean n of annual hospital
visits are presented in figure a), inpatient days in figure b)
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health care system and data sources available are differ-
ent from the ones used in the present study [3, 12]. Dur-
ing the past two decades, the biggest change in the
treatment of MF/SS patients has been in the mean num-
ber of MF/SS-related inpatient days, which decreased to
one third between 2007 (6.7 annual inpatient days per
patient) and 2009 (2.1 annual inpatient days per patient).
There has been a general tendency to treat patients with
chronic diseases as outpatients instead of hospitalisation
in Finland, which could partly explain this finding. MF/
SS specific treatment practices in Finland have also
changed in the past two decades: previously, patients
undergoing phototherapy or skin-directed therapy were
usually hospitalised in the beginning of the new treat-
ment. More recently these treatments have been per-
formed in an outpatient manner. Also, the use of
bexarotene, which does not require inpatient monitoring
of the patient, has become widespread as a first-line sys-
temic therapy for MF/SS [13]. Further research would
be needed to support these potential explanations for
the decrease in inpatient care of MF/SS patients.
Unlike inpatient stays, the number of outpatient visits
has remained constant for the past two decades, on aver-
age eight annual visits per patient. In clinical practice
these visits typically include the regular follow-up visits
(three or four per year depending on the stage of the dis-
ease) as well as the visits due to the sudden exacerba-
tions of the lymphoma and other acute illnesses. We
assume that inpatient treatment has been to some extent
replaced by outpatient visits. Interestingly, this has not
lead to an increase in the mean number of outpatient
visits. This may be due to improved outpatient-based
treatment protocols, or improved disease control.
Most MF/SS-related hospital visits and inpatient days
have occurred in dermatological clinics throughout the
20-year inspection period. A minority of hospital visits
occurred in oncology. This usually happens in the later
stages of the disease, when oncological treatment, e.g.
chemotherapy is started.
MF/SS patients have been reported to have a high bur-
den of comorbidities, in particular other cancers and de-
pression [4, 5]. This was considered also in the design of
the present study, as all secondary health care use of
MF/SS patients was reported by cause for a cohort of
247 incident MF/SS patients for 10 years following diag-
nosis. The most common reasons for hospital visits and
inpatient days among MF/SS patients were in line with
existing comorbidity literature [4, 5]. Other cancers, dis-
ease of the skin and subcutaneous tissue, cardiovascular
disease, and pneumonia and other infections were
reflected especially in the number of inpatient days
among MF/SS patients. The mean number of hospital
visits during year of diagnosis for MF/SS (7.3) or for any
reason including MF/SS (17.6) were in the same range
with physician office visits recently reported in a claims
database analysis from the United States, in which health
care use during index year was observed for 1981 MF
patients with the same health insurance company [6].
Health care costs were highest at the year of MF/SS
diagnosis, after which they declined until reaching a
steady stage at year four. The diagnosis of MF is challen-
ging and the delay from the first symptoms to diagnosis
is 4–6 years [14]. During the first year, the diagnostic
procedures, including e.g. immunohistology, molecular
cytogenetics and disease staging, make up a big part of
the costs. The patient also needs more guidance and
support in terms of frequent visits.
Previous information about the costs of treating MF/
SS is limited, particularly in a European setting [6, 7]. As
this study relied on standard methods of health eco-
nomic evaluation - nationwide registers combined with
national standard unit costs and patient grouping sys-
tems - health care use of MF/SS patients may now be
compared with other patient groups to better under-
stand the burden of disease. For instance, during the first
4 years after MF/SS diagnosis, the mean costs per pa-
tient are 8- to 16-fold compared with the general popu-
lation of Finland [15]. After this, the mean numbers of
Table 1 Mean hospital treatment costs of MF/SS patients in 10-year follow-up after diagnosis
Year n (MF) n (SS) MF/SS treatment costs (mean €/patient) Other disease costs (mean €/patient) Mean MF/SS share of total costs (%)
0 207 40 11,630 11,107 51
1 173 27 9804 6619 60
2 147 15 5854 4136 59
3 135 15 6194 5284 54
4 119 15 2700 3751 42
5 112 15 3928 4078 49
6 103 15 2892 3298 47
7 100 15 2485 5288 32
8 94 15 2632 4283 38
9 86 15 3613 4720 43
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hospital visits and inpatient days stabilise, which could
be partially due to changes in the cohort population. It
is reasonable to assume that the patients who were high
utilisers of health care close to MF/SS diagnosis died
sooner, while patients with a more indolent disease and
less comorbidities remained in the cohort. Also, if the
patient moves to a heavily supported environment such
as a nursing home, their health care costs are transferred
from the health care sector to the social sector and are
thus not visible in the present study. In another Finnish
dataset, the cumulative hazard for death or institutionali-
sation was 14% 1 year from MF/SS diagnosis, 19% 2
years from diagnosis, and 26% 3 years from diagnosis
(n = 102) (Additional file 2). This is approximately simi-
lar to the loss to follow-up in the present study. A future
prospect would be to further characterise health care
use and cost distribution among MF/SS patients by iden-
tifying medication and treatment strategies which are as-
sociated with higher costs and morbidity.
The major uncertainty of the study relates to the quality
of the data in the national discharge register held by the
National Institute for Health and Welfare. While the dis-
charge register is regularly checked for completeness and
accuracy, there has been no MF/SS specific audit [8]. Des-
pite its name, the discharge register includes information
also on all patients who have been treated in an outpatient
setting in the secondary health care sector, which is re-
sponsible for diagnosing and treatment of all cancers in
Finland. It is thus reasonable to assume that all patients
who have received a MF/SS diagnosis in Finland are rep-
resented in our data. However, as previous research re-
ports a mean time of 4–6 years from the onset of
symptoms to diagnosis of MF, the true prevalence could
be somewhat higher than the diagnosed prevalence we re-
port [14]. Another limitation of the study is the level of
detail we are able to provide in terms of patient character-
istics. As we only had access to aggregate level, grouped
data on health care use among the total MF/SS patient
population at any given year, we were unable to standard-
ise our health care use results according to patient charac-
teristics such as age and sex.
Conclusions
In this paper, we have presented trends in prevalence,
and secondary health care use of mycosis fungoides and
Sézary syndrome patients in Finland over a time period
of two decades. The nearly three-fold increase in preva-
lence of diagnosed MF/SS during 1998–2016 puts pres-
sure on the health care system, as this is a high-cost
patient group with a heavy burden of comorbidities. The
challenge can be in part answered by shifting the treat-
ment of MF/SS to a more outpatient-based practice, and
by adapting new pharmacotherapy, as has been done in
Finland.
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